Answers are grounded in this paper and cite their sources.
The capability of pravastatin and lovastatin, HMG-CoA reductase inhibitors likely to be taken chronically for hypercholesterolemia, to cross the blood-brain barrier was investigated in normal male volunteers. Lovastatin, which is lipophilic, was detected in cerebrospinal fluid (CSF) at concentrations that may have a pharmacologic effect. Pravastatin, which is hydrophilic, was not detected in CSF. It is concluded that pravastatin may have less potential for causing CNS-related side effects than lovastatin.
No takes yet. Share an insight, caveat, or question.
Botti et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: